Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant plus DNA damage repair inhibitors in HR-positive advanced breast cancer after CDK4/6 inhibitor
KCT0007776Phase 2Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulvestrant in breast cancer, sponsored by Seoul National University Hospital. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0007776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007776.